Preparation method of musk fluid extract for dispelling wind and relieving pain and external preparation containing musk fluid extract
By adjusting the medicinal material levels and non-woven fabric settings in the permeation extraction process, the problem of difficult extraction amounts of aconitine and sidine in Musk Zhuifeng Pain Relieving Paste is solved, and the product's high pass rate and process stability are achieved. Reduced production costs.
Patent Information
- Application Number
- CN202411158929.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, the production method of Musk Wind Pain Relieving Paste causes the content of the finished product to not meet the standards, and the product unqualified rate is relatively high, especially the extraction amount of aconitine and Sidening is difficult to control, resulting in a high scrap rate.
Using a specific permeation extraction process, the first toxic medicinal powder after crushing the macadamia pulverizes the first toxic medicinal material coarse powder on the bottom of the permeation tank, and the other medicinal material coarse powder in the middle, and then the second toxic medicinal material coarse powder on the upper layer, and Lay 200 to 400 mesh non-woven fabrics between each layer, control the liquid level height and permeation speed of the ethanol solution, and collect the permeation solution to ensure that the content of aconitine, stinine and stecone meets the standards.
The 100% pass rate of the aconitine, sidin and stechinine content of Musk Wind Pain Relieving Ointment has been achieved, which has improved the pass rate and process stability of the product and reduced production costs.
Smart Images

Figure BDA0005005876650000111 
Figure BDA0005005876650000121
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of preparation technology of Chinese patent medicines, and in particular to a preparation method of a musk wind-chasing and analgesic fluid extract and an external preparation containing the fluid extract. Background Art
[0002] Musk Wind-Chasing Pain-Relieving Cream is a medicine prepared from Musk Wind-Chasing Liquid Extract (raw Aconite, raw Chuanwu, frankincense, myrrh, raw Strychnos nux vomica, clove, cinnamon, schizonepeta, siler, geranium, Perennial Cortex, Centella Asiatica, Drynaria, Angelica Dahurica, Kaempferia galanga, dried ginger and artificial musk), camphor, menthol, borneol, methyl salicylate, Rue Extract (Rue) and Atropa belladonna Extract (Atropa belladonna) as raw materials, which has good anti-inflammatory and analgesic effects, and has significant therapeutic effects on joint pain, tenderness, flexion and extension difficulties and morning stiffness caused by rheumatism. The drug is indicated for joint and muscle pain caused by cold and dampness, and sprain pain.
[0003] Among them, Musk Chasing Wind Fluid Extract is the key raw material ingredient, containing toxic Chinese medicinal materials raw aconite, raw Chuanwu and raw Strychnos nux vomica. Musk Chasing Wind Pain Relief Paste has certain requirements for the content of the characteristic ingredients of toxic Chinese medicinal materials. The Musk Chasing Wind Pain Relief Paste standard limits aconitine, and also has clear requirements for the content of strychnine and strychnine. The product can only be considered qualified if the aconitine limit, strychnine and strychnine content are all qualified at the same time. The above regulations make the control of the extraction process very difficult. The aconitine requirement cannot exceed a certain limit. Extracting too much aconitine will lead to toxic reactions. The strychnine limit in Strychnos nux vomica in the product is 16-48μg. Extracting too much strychnine will produce toxicity, and extracting too little will lead to poor analgesic effect). The content of strychnine shall not be less than 6.5μg / patch. Since there are too many limiting factors in Musk Wind-Chasing Pain-Relieving Ointment, it is difficult to effectively guarantee the qualified rate of the product, resulting in a high scrap rate and huge losses. Therefore, it is urgent to find a preparation process control method for Musk Wind-Chasing Pain-Relieving Fluid Extract. Summary of the invention
[0004] The present invention aims to provide a method for preparing a musk wind-chasing analgesic fluid extract, so as to solve the technical problem that the production method of the musk wind-chasing fluid extract in the prior art leads to the content of toxic components in the finished product not meeting the standard and a high product failure rate.
[0005] In order to achieve the above object, the present invention adopts the following technical scheme:
[0006] A method for preparing a musk wind-chasing and analgesic fluid extract comprises the following steps performed in sequence:
[0007] S1: crushing the seeds of Strychnos nux vomica to obtain a first toxic medicinal material coarse powder; mixing and crushing the Radix Aconiti Kusnezoffii and Radix Aconiti Kusnezoffii to obtain a second toxic medicinal material coarse powder; mixing and crushing frankincense, myrrh, cloves, cinnamon bark, schizonepeta, siler, geranium, radix scutellariae, centella asiatica, rhizoma drynariae, angelica dahurica, galangal, and dried ginger to obtain other medicinal material coarse powders;
[0008] S2: placing the first toxic medicinal material coarse powder, other medicinal material coarse powders and the second toxic medicinal material coarse powder into a percolation tank in order from bottom to top; laying non-woven fabric between adjacent coarse powder layers, and then percolating with an ethanol solution to collect the percolation liquid;
[0009] S3: After the percolate is concentrated, artificial musk is added to obtain the musk wind-chasing and analgesic fluid extract.
[0010] The invention also provides a musk wind-chasing and analgesic fluid extract prepared according to a preparation method of the musk wind-chasing and analgesic fluid extract.
[0011] The present invention also provides an external preparation using the Musk Wind-Chasing and Pain-Relieving Fluid Extract of the scheme as a raw material. The external preparation is Musk Wind-Chasing and Pain-Relieving Paste.
[0012] The technical scheme also provides a preparation method of musk wind-chasing and analgesic ointment, comprising the steps of mixing musk wind-chasing and analgesic fluid extract and belladonna fluid extract to obtain a first mixed extract; mixing camphor, borneol, methyl salicylate, menthol and rue extract to obtain a second mixed extract; mixing the first mixed extract and the second mixed extract, adding a matrix composed of rubber, rosin, zinc oxide, vaseline, lanolin and liquid paraffin, mixing the mixture to form a coating, applying the ointment, cutting into sections, covering with a backing, and cutting into blocks to obtain the ointment.
[0013] Furthermore, in S1, the first toxic medicinal material coarse powder, the second toxic medicinal material coarse powder and the other medicinal material coarse powders are all obtained by crushing the medicinal materials and then passing through a 16-20 mesh sieve.
[0014] Furthermore, in S1, before being crushed, the seeds of Strychnos nux vomica, Aconiti kusnezoffii and Aconitum kusnezoffii are all dried at 40-60° C. to a moisture content of less than 5%.
[0015] Further, in S2, the pore size of the non-woven fabric is 200-400 mesh;
[0016] Preferably, the percolation process in S2 is specifically as follows: adding 80% to 95% ethanol solution to the percolation tank, the ratio of ethanol solution to the total mass of medicinal materials being 1.5 to 2.5 L: 1 kg, and then sealing and placing for 3 to 5 hours; then adding 80% to 95% ethanol solution, keeping the stacking height of the medicinal material coarse powder at 2.9 to 3.1 m, and keeping the liquid level of the ethanol solution 40 to 60 cm higher than the upper surface of the medicinal material coarse powder; finally, performing the percolation operation after immersion for 45 to 55 hours, and the percolation speed being 1 to 3 ml / min. kg -1; Collect the percolation liquid, the ratio of the percolation liquid to the medicinal materials is 8-12L:1kg.
[0017] Preferably, in S2, the stacking height of the crude medicinal material powder is preferably 3.0 m.
[0018] Further, in S3, the percolation liquid is first concentrated into a semi-finished extract, the relative density of the semi-finished extract is 1.24-1.26 at 40-55°C; then anhydrous ethanol is added to the semi-finished extract, the mixture is stirred evenly and allowed to stand, and the supernatant is taken. The usage ratio of anhydrous ethanol to the semi-finished extract is 8-12L:1kg.
[0019] Further, in S3, the supernatant is filtered through a 80-120 mesh sieve and concentrated to a relative density of 1.05-1.07 at 40-55° C., and then artificial musk is added and mixed to obtain the musk wind-chasing and analgesic fluid extract.
[0020] Furthermore, the raw materials of the musk wind-chasing and analgesic fluid extract are, in parts by weight: 40-50 parts of raw Chuanwu, 40-50 parts of raw Caowu, 40-50 parts of frankincense, 40-50 parts of myrrh, 40-50 parts of raw Strychnos nux vomica, 40-50 parts of cloves, 80-90 parts of cinnamon, 80-90 parts of Schizonepeta, 80-90 parts of Saposhnikovia divaricata, 80-90 parts of Geranium, 80-90 parts of Perennial Cyperus, 80-90 parts of Centella asiatica, 80-90 parts of Drynaria, 130-140 parts of Angelica dahurica, 130-140 parts of Kaempferia galanga, 130-140 parts of dried ginger, and 0.2-0.3 parts of artificial musk.
[0021] Furthermore, the musk wind-chasing analgesic ointment comprises, in parts by weight, 50-60 parts of musk wind-chasing analgesic fluid extract, 20-25 parts of camphor, 10-15 parts of borneol, 14-20 parts of methyl salicylate, 20-25 parts of menthol, 12-18 parts of rue extract, and 30-40 parts of belladonna extract.
[0022] The principle and beneficial effects of this technical solution are:
[0023] With the current process, the finished product of Musk Wind-Chasing Pain-Relieving Paste often has the problem of aconitine exceeding the limit and strychnine below the limit, which seriously affects the product qualification rate. How to reduce the extraction amount of aconitine and increase the extraction amount of strychnine at the same time with a simple and low-cost process method is the key problem to be solved in this scheme. The inventor has found through a lot of research that to ensure that the indicators of aconitine, strychnine and strychnine of Musk Wind-Chasing Pain-Relieving Paste meet the requirements, and then to ensure that the product qualification rate is close to 100%, it is necessary to adopt the following conditions during the percolation extraction process: the first toxic medicinal material coarse powder (strychnine) is placed at the bottom of the extraction tank, other medicinal material coarse powders are placed in the middle, and then the coarse powder of the second toxic medicinal material (Chuanwu, Caowu) is placed on the upper layer; and a non-woven fabric (200-400 mesh) of a certain aperture is laid between each layer; during the percolation extraction process, the liquid level of the percolation liquid is maintained at a certain height (3.4-3.6 meters, 40-60cm away from the medicinal material coarse powder pile).
[0024] The present technical solution was used to prepare multiple batches of Musk Wind-Chasing Pain-Relieving Cream. The qualified rate was 100% in terms of the limit index of aconitine; the qualified rate was 100% in terms of the range of strychnine content; and the qualified rate was 100% in terms of strychnine content. This shows that the process method of the present solution has greatly improved the qualified rate and process stability of Musk Wind-Chasing Pain-Relieving Cream. The present technical solution can solve the technical problem that the production method of Musk Wind-Chasing Fluid Extract in the prior art results in the content of toxic components in the finished product not meeting the standard and a high rate of product failure. DETAILED DESCRIPTION
[0025] The following examples are only used to more clearly illustrate the technical solutions of the present invention, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present invention. The specific embodiments listed in the present invention are only examples of the present invention, and the present invention is not limited to the specific embodiments described below. For those skilled in the art, any equivalent modifications and substitutions to the embodiments described below are also within the scope of the present invention. Therefore, equal transformations and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention. In order to better illustrate the present invention, numerous specific details are given in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art.
[0026] Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production. Unless otherwise specified, the experimental methods used in the following implementations are all conventional methods; the materials, reagents or instruments used without indicating the manufacturer are all reagents and materials that can be obtained from commercial channels. If no specific conditions are specified in the examples, they are all carried out according to conventional conditions or conditions recommended by the manufacturer. At the same time, the present invention does not limit the sources of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all common commercial products in the field of this technology.
[0027] It should be noted that the names of the medicinal materials used in the following examples and their quality standards are uniformly described in Table 1:
[0028] Table 1: Names and quality standards of various raw medicinal materials (Musk Zhuifeng fluid extract)
[0029] serial number Material / Product Name Latin name Mass fraction 1 Aconitum kusnezoffii (raw) ACONITI KUSNEZOFFII RADIX 40~50 servings 2 Chuanwu (raw) ACONITI RADIX 40~50 servings 3 mastic OLIBANUM 40~50 servings 4 Myrrh MYRRHA 40~50 servings 5 clove CARYOPHYLLI FLOS 40~50 servings 6 Nux vomica (raw) STRYCHNI SEMEN 40~50 servings 7 Cinnamon CINNAMOMI CORTEX 80~90 servings 8 Nepeta SCHIZONEPETAE HERBA 80~90 servings 9 Geranium ERODII HERBA 80~90 servings 10 Windproof SAPOSHNIKOVIAE RADIX 80~90 servings 11 Perilla frutescens PERIPLOCAE CORTEX 80~90 servings 12 Centella asiatica CENTELLAE HERBA 80~90 servings 13 Drynaria fortunei DRYNARIAE RHIZOMA 80~90 servings 14 Shannai KAEMPFERIA RHIZOMA 130~140 servings 15 Dried ginger ZINGIBERIS RHIZOMA 130~140 servings 16 Angelica dahurica ANGELICAE DAHURICAE RADIX 130~140 servings 17 Artificial Musk MOSCHUS 0.2~0.3 parts
[0030] Example 1
[0031] The formula of the present embodiment is specifically:
[0032] 45 parts of raw Chuanwu, 45 parts of raw Caowu, 45 parts of frankincense, 45 parts of myrrh, 45 parts of raw Strychnos nux vomica, 45 parts of cloves, 85 parts of cinnamon, 85 parts of Nepeta, 85 parts of Saposhnikovia divaricata, 85 parts of Geranium, 85 parts of Cyperus rotundus, 85 parts of Centella asiatica, 85 parts of Drynaria fortunei, 135 parts of Angelica dahurica, 135 parts of Kaempferia galanga, 135 parts of dried ginger, and 0.2 parts of artificial musk.
[0033] Musk wind-chasing and pain-relieving ointment fluid extract is prepared according to the following method:
[0034] (I) Pre-treatment:
[0035] (1) Crushing of toxic medicinal material 1: Take raw Strychnos nux vomica, dry it at 40-60° C. (50° C. in this embodiment) until the moisture content is less than 5%, grind it with a 30B air-cooled grinder and pass it through a 16-20 mesh sieve (16 mesh in this embodiment), and collect the coarse powder for later use (first toxic medicinal material coarse powder).
[0036] (2) Crushing treatment of toxic medicinal material 2: Take raw Chuanwu and raw Caowu, dry them at 40-60°C (50°C in this embodiment) until the moisture content is less than 5%, and after coarse mixing, crush them with a 30B air-cooled crusher to pass through a 16-20 mesh sieve (16 mesh in this embodiment), mix them in a two-dimensional motion mixer for 10-20 minutes (15 minutes in this embodiment), and collect the coarse powder for later use (coarse powder of the second toxic medicinal material).
[0037] (3) Grinding of other medicinal materials: Take thirteen medicinal pieces of frankincense, myrrh, clove, cinnamon bark, schizonepeta, siler, geranium, balsam pear, centella asiatica, drynaria, angelica dahurica, galangal, and dried ginger, mix them initially, grind them with a 30B air-cooled grinder, pass through a 16-20 mesh sieve (specifically, 16 mesh is used in this embodiment), mix them in a two-dimensional motion mixer for 10-20 minutes (specifically, 15 minutes is used in this embodiment), and collect the coarse powder for later use (coarse powder of other medicinal materials).
[0038] (ii) Percolation:
[0039] Put the first toxic medicinal material coarse powder into the bottom of the conventional percolation tank in the prior art, gently level it, and lay a layer of 200-400 mesh non-woven fabric (400 mesh is specifically used in this embodiment) that is basically the same as the diameter of the percolation tank, then add other medicinal material coarse powders, gently level them, and lay another layer of 200-400 mesh non-woven fabric (400 mesh is specifically used in this embodiment), and finally fill in the second toxic medicinal material coarse powder.
[0040] Use 80-95% ethanol to evenly wet the medicinal materials in the percolation tank, and the ratio of ethanol solution to the total mass of medicinal materials is 1.5-2.5L:1kg (this embodiment specifically uses 90% ethanol solution, and ethanol solution: total mass of medicinal materials to be percolated = 1.5L:1kg), seal the percolation tank, and leave it for 3-5 hours (this embodiment specifically uses 4 hours). Add ethanol solution to keep the height from the bottom surface to the liquid level at 3.4-3.6 meters (that is, the liquid level is 40-60cm higher than the upper surface of the medicinal material coarse powder pile, and the height of the medicinal material coarse powder pile is 2.9-3.1 meters; this embodiment specifically uses 3.5 meters, the height of the medicinal material powder columnar pile is 3.0 meters, and the percolation liquid level is 50cm higher than the upper surface of the medicinal material coarse powder pile). After immersion for 45-55 hours (this embodiment specifically uses 48 hours), at 1-3ml / min﹒ kg -1 (The outflow rate per kg of medicinal material is 1-3 ml per minute, and this embodiment specifically adopts 2 ml / min. -1 ) to collect about 8 to 12 times the amount of medicinal materials (in terms of volume L, the ratio of the percolation liquid to the mass of the medicinal materials used for percolation extraction is 8 to 12 L: 1 kg, and 10 times is specifically used in this embodiment) of the percolation liquid.
[0041] (III) Preparation of semi-finished extract:
[0042] The percolate was concentrated to a relative density of 1.24 to 1.26 (at 40 to 55° C., specifically at 50° C. in this embodiment, with a relative density of about 1.25) using a single-effect concentrator to prepare a semi-finished extract.
[0043] (IV) Alcohol precipitation:
[0044] The obtained semi-finished product extract is cooled, and 8 to 12 times the volume of ethanol is added (the ratio of anhydrous ethanol to the semi-finished product extract is 8 to 12 L: 1 kg, and 10 times is specifically used in this embodiment), and the mixture is stirred and mixed evenly, and the mixture is allowed to stand for 20 to 30 hours (specifically 24 hours in this embodiment), and the supernatant is taken.
[0045] (V) Filtration, recovery and concentration:
[0046] The supernatant obtained by alcohol precipitation is filtered through 80-120 mesh (100 mesh is used in this embodiment), sucked into a single-effect concentrator, ethanol is recovered and concentrated to a relative density of 1.05-1.07 (40-55°C, specifically 50°C in this embodiment, with a relative density of about 1.06), the recovered concentrated medicinal liquid is transferred to a 500L spherical concentrator, artificial musk is added, and stirring is started for 20-30 minutes (15 minutes in this embodiment), and the musk wind-chasing and analgesic fluid extract is collected.
[0047] Musk wind-chasing analgesic fluid extract is an intermediate of Musk Wind-Chasing Analgesic Paste product (see the national standard WS-11370 (ZD-1370)-2002-2012Z-2019 of Musk Wind-Chasing Analgesic Paste), and is an intermediate raw material of conventional Chinese patent medicine in the prior art. This technical scheme aims to improve the intermediate raw material.
[0048] Example 2
[0049] This embodiment is basically the same as embodiment 1, except for the dosage and preparation parameters.
[0050] The formula of the present embodiment is:
[0051] 40 parts of raw Chuanwu, 40 parts of raw Caowu, 40 parts of frankincense, 40 parts of myrrh, 40 parts of raw Strychnos nux vomica, 40 parts of cloves, 80 parts of cinnamon, 80 parts of Nepeta, 80 parts of Saposhnikovia divaricata, 80 parts of Geranium, 80 parts of Cyperus rotundus, 80 parts of Centella asiatica, 80 parts of Drynaria, 130 parts of Angelica dahurica, 130 parts of Kaempferia galanga, 130 parts of dried ginger, and 0.2 parts of artificial musk.
[0052] Musk wind-chasing and pain-relieving ointment fluid extract is prepared according to the following method:
[0053] (I) Pre-treatment:
[0054] (1) Crushing of toxic medicinal material 1: Take raw Strychnos nux vomica, dry it at 40°C until the moisture content is less than 5%, grind it with a 30B air-cooled grinder and pass it through a 16-mesh sieve, and collect the coarse powder for later use (the first toxic medicinal material coarse powder).
[0055] (2) Crushing treatment of toxic medicinal material 2: Take raw Chuanwu and raw Caowu, dry them at 40°C until the moisture content is less than 5%, and after coarse mixing, crush them with a 30B air-cooled crusher to pass through a 16-mesh sieve, mix them in a two-dimensional motion mixer for 10 minutes, and collect the coarse powder for later use (second toxic medicinal material coarse powder).
[0056] (3) Grinding of other medicinal materials: Take 13 kinds of medicinal pieces including frankincense, myrrh, clove, cinnamon bark, schizonepeta, siler, geranium, cyperus rotundus, centella asiatica, drynaria, angelica dahurica, galangal, and dried ginger, mix them initially, grind them with a 30B air-cooled grinder and pass through a 16-mesh sieve, mix them in a two-dimensional motion mixer for 10 minutes, and collect the coarse powder for later use (coarse powder of other medicinal materials).
[0057] (ii) Percolation:
[0058] Put the first toxic medicinal material coarse powder into the bottom of the percolation tank, gently level it, and lay a layer of 200-mesh non-woven fabric that is basically the same as the diameter of the percolation tank. Then add other medicinal material coarse powders, gently level them, and lay another layer of 200-mesh non-woven fabric. Finally, fill in the second toxic medicinal material coarse powder, add 1.5 times the volume of 80% ethanol to mix, wet it evenly, seal the percolation tank, leave it for 3 hours, add ethanol solution, and keep the height from the bottom surface to the liquid level to reach 3.4 meters. The height of the medicinal material powder columnar accumulation is 3.0 meters (the percolation liquid level is 40cm higher than the upper surface of the medicinal material coarse powder pile). After immersion for 45 hours, at 1ml / min﹒ kg -1 The percolation was slowly performed at a speed of 100 °C and about 8 times the amount of medicinal materials were collected.
[0059] (III) Preparation of semi-finished extract:
[0060] The single-effect concentrator is started, the percolate from the tank is sucked into the single-effect concentrator, ethanol is recovered under reduced pressure and concentrated to a relative density of about 1.25 (40° C.), and a semi-finished extract is prepared.
[0061] (IV) Alcohol precipitation:
[0062] The semi-finished extract was cooled, 8 times the volume of ethanol was added, the mixture was stirred and mixed thoroughly, and the mixture was allowed to stand for 20 hours, and the supernatant was collected.
[0063] (V) Filtration, recovery and concentration:
[0064] The supernatant obtained by alcohol precipitation was filtered through 80 mesh, sucked into a single-effect concentrator, ethanol was recovered and concentrated to a relative density of about 1.05 (40°C), the recovered concentrated medicinal liquid was transferred to a 500L spherical concentration tank, artificial musk was added, and stirring was started for 20 minutes to collect the musk wind-chasing and analgesic fluid extract.
[0065] Example 3
[0066] This embodiment is basically the same as embodiment 1, except for the dosage and preparation parameters.
[0067] The formula of the present embodiment is:
[0068] 50 parts of raw Chuanwu, 50 parts of raw Caowu, 50 parts of frankincense, 50 parts of myrrh, 50 parts of raw Strychnos nux vomica, 50 parts of cloves, 90 parts of cinnamon, 90 parts of Nepeta, 90 parts of Saposhnikovia divaricata, 90 parts of Geranium, 90 parts of Cyperus rotundus, 90 parts of Centella asiatica, 90 parts of Drynaria, 140 parts of Angelica dahurica, 140 parts of Kaempferia galanga, 140 parts of dried ginger, and 0.3 parts of artificial musk.
[0069] Musk wind-chasing and pain-relieving ointment fluid extract is prepared according to the following method:
[0070] (I) Pre-treatment:
[0071] (1) Crushing of toxic medicinal material 1: Take raw Strychnos nux vomica, dry it at 60°C until the moisture content is less than 5%, grind it with a 30B air-cooled grinder and pass it through a 20-mesh sieve, and collect the coarse powder for later use (the first toxic medicinal material coarse powder).
[0072] (2) Crushing treatment of toxic medicinal material 2: Take raw Chuanwu and raw Caowu, dry them at 60°C until the moisture content is less than 5%, and after coarse mixing, crush them with a 30B air-cooled crusher to pass through a 20-mesh sieve, mix them in a two-dimensional motion mixer for 20 minutes, and collect the coarse powder for later use (second toxic medicinal material coarse powder).
[0073] (3) Grinding of other medicinal materials: Take 13 medicinal pieces of frankincense, myrrh, clove, cinnamon, schizonepeta, siler, geranium, cyperus rotundus, Centella asiatica, drynaria, angelica dahurica, galangal, and dried ginger, mix them initially, grind them with a 30B air-cooled grinder and pass through a 20-mesh sieve, mix them in a two-dimensional motion mixer for 20 minutes, and collect the coarse powder for later use (coarse powder of other medicinal materials).
[0074] (ii) Percolation:
[0075] Put the first toxic medicinal material coarse powder into the bottom of the percolation tank, gently level it, and lay a layer of 400-mesh non-woven fabric that is basically the same as the diameter of the percolation tank. Then add other medicinal material coarse powders, gently level them, and lay another layer of 400-mesh non-woven fabric. Finally, fill in the second toxic medicinal material coarse powder, add 2.5 times the volume of 95% ethanol to mix, wet it evenly, seal the percolation tank, leave it for 5 hours, add ethanol solution, and keep the height from the bottom surface to the liquid level to reach 3.6 meters. The height of the medicinal material powder columnar accumulation is 3.0 meters (the percolation liquid level is 60cm higher than the upper surface of the medicinal material coarse powder pile). After immersion for 55 hours, at 3ml / min﹒ kg -1 The percolation was slowly performed at a speed of 100 °C and about 12 times the amount of medicinal materials were collected.
[0076] (III) Preparation of semi-finished extract:
[0077] The single-effect concentrator is started, the percolate from the tank is sucked into the single-effect concentrator, ethanol is recovered under reduced pressure and concentrated to a relative density of about 1.26 (55° C.), and a semi-finished extract is prepared.
[0078] (IV) Alcohol precipitation:
[0079] The semi-finished extract was cooled, 12 times the volume of ethanol was added, the mixture was stirred and mixed thoroughly, and the mixture was allowed to stand for 30 hours, and the supernatant was collected.
[0080] (V) Filtration, recovery and concentration:
[0081] The supernatant obtained by alcohol precipitation was filtered through 120 mesh, sucked into a single-effect concentrator, ethanol was recovered and concentrated to a relative density of about 1.07 (55°C), the recovered concentrated medicinal liquid was transferred to a 500L spherical concentration tank, artificial musk was added, and stirring was started for 30 minutes to collect the musk wind-chasing and analgesic fluid extract.
[0082] Comparative Example 1
[0083] This comparative example is a traditional preparation method of Musk Zhuifeng liquid extract, the formula is according to Example 1, and the preparation process is as follows:
[0084] Mix the pieces of other medicinal materials except artificial musk, crush them with a 30B air-cooled grinder and pass them through a 16-mesh sieve, mix them in a two-dimensional motion mixer for 15 minutes to obtain coarse powder. Put the coarse powder into a percolation tank, add 1.5 times the volume of 90% ethanol and mix. Wet it evenly, seal the percolation tank, and leave it for 4 hours. Then, add 90% ethanol, keep the ethanol solution above the surface of the medicinal materials, soak for 48 hours, and then purify it at 2ml / min﹒ kg -1 The percolation was performed slowly at a speed of about 1:1 to collect the percolation liquid which was about 10 times the amount of the medicinal material. The subsequent operation was the same as in Example 1.
[0085] The Musk Wind-Chasing Fluid Extract is prepared according to the traditional method, and then the Musk Wind-Chasing Pain-Relieving Ointment is prepared, but there are the following defects:
[0086] (1) According to the national standard WS-11370 (ZD-1370)-2002-2012Z-2019 of Musk Wind-Chasing Pain-Relieving Cream, the content of aconitine in the Musk Wind-Chasing Pain-Relieving Cream needs to be controlled. The specific method is as follows:
[0087] [Inspection] Aconitine limit - Take 1.5g of this product, add 10ml of chloroform, shake to dissolve, shake and extract with 0.5molL sulfuric acid solution 5 times (20ml, 10ml, 10ml, 10ml, 10ml), combine the acid solution, add concentrated ammonia test solution to adjust the pH value to 9-10, shake and extract with chloroform 5 times (30ml, 20ml, 20ml, 20ml, 20ml), combine the chloroform solution, recover the solvent to dryness, add 2ml of methanol to the residue to dissolve, filter, and take the filtrate as the test solution. Take another aconitine reference substance, add methanol to make a solution containing 0.4mg per 1ml as the reference substance solution. According to the thin layer chromatography method (Chinese Pharmacopoeia 2015 Edition General Principle 0502), take the above test solution 20ul1l and reference solution 3ul, and spot them on the same silica gel G thin layer plate, use the lower layer solution of chloroform-ethyl acetate-concentrated ammonia test solution (5:5:1) as the developing agent, develop, take out, dry, and spray with dilute potassium bismuth iodide test solution. In the chromatogram of the test sample, the spot that appears at the corresponding position of the chromatogram of the reference should be smaller than the spot of the reference, or no spot should appear.
[0088] According to the finished product obtained by the traditional method as shown in this comparative example, the limit of aconitine will appear in some batches exceeding the standard (exceeding the standard to produce toxicity), resulting in unqualified products, which are specifically manifested as: referring to the inspection method of the aforementioned limit of aconitine, the content of aconitine in the product is checked, and the inspection results often appear as follows: the spots appearing on the corresponding positions of the test sample chromatogram and the reference substance thin-layer chromatogram are similar in size to the reference substance spots, and it is not possible to clearly judge whether the sample is qualified in the limit of aconitine. Usually, in order to ensure the quality and safety of listed products, such products need to be classified as unqualified products in production, because unqualified products need to be abandoned, which will lead to higher production costs. According to statistics from the production department of the enterprise, according to the preparation method of this comparative example, multiple batches of Musk Wind Chasing Pain Relief Cream are produced. For the limit index of aconitine, the annual qualified rate in the past 10 years has been maintained in the range of 75% to 81% (the annual qualified rate is calculated as follows: the proportion of qualified batches per year to the total production batches, and the statistical year is 2013-2023). It can be seen that the qualified rate of the production process of the prior art is not ideal and needs to be further improved. Since the content of aconitine in the fluid extract prepared by the current process is slightly higher, after the finished patch is prepared with the fluid extract, due to the complexity of the process and raw materials (some fluctuations occur), the content of aconitine in the finished product often approaches or exceeds the critical value. Only by further limiting the content of aconitine in the fluid extract can we ensure that the above situation does not occur. Because after the content of aconitine in the fluid extract is further controlled and reduced (reduced to a certain level), even if there are some fluctuations in the process, the content of aconitine in the finished product will not approach or exceed the critical value of the limit.
[0089] (2) The standard for Musk Wind-Chasing Pain-Relieving Ointment (WS-11370 (ZD-1370)-2002-2012Z-2019) has clear requirements for the content of strychnine and brucine: Each patch of this product contains strychnine (C 21 H 22 N 2 O 2 ) should be 16-48 μg; based on strychnine (C 23 H 26 N 2 O 4 ) shall not be less than 6.5μg.
[0090] According to the traditional method of comparative example 1, some production batches of Musk Wind-Chasing Pain-Relieving Ointment obtained are difficult to meet the above standards. The Musk Wind-Chasing Pain-Relieving Ointment prepared by the Musk Wind-Chasing Fluid Extract of this comparative example method is used for the preparation of Musk Wind-Chasing Pain-Relieving Ointment (the preparation method is detailed in the application example). The strychnine content usually meets the above index requirements, while the strychnine content will be lower than the lower limit of the index. The unqualified product needs to be abandoned, which further leads to an increase in production costs. According to statistics, according to the preparation method of this comparative example, according to the statistics of the production department of the enterprise, according to the preparation method of this comparative example, multiple batches of Musk Wind-Chasing Pain-Relieving Ointment are produced. For the range of strychnine content, the annual qualified rate in the past 10 years has remained at 78% to 85% (the annual qualified rate is calculated as follows: the proportion of qualified batches per year to the total production batches, and the statistical years are 2013-2023). It can be seen that the qualified rate of the production process of the prior art is not ideal and needs to be further improved. The reason for the above unqualified phenomenon is mainly that the current process is low in the extraction amount of strychnine. If there is a process fluctuation, it is easy to cause the strychnine content in the finished product to be lower than the lower limit. It is necessary to further improve the extraction level of strychnine so that the strychnine content in the finished product exceeds a larger value within the minimum range. In this way, even if there are certain process fluctuations, it will not lead to the situation where the indicator is unqualified. In addition, increasing the strychnine content within a certain range will also improve the effect of the finished product.
[0091] Comparative Example 2
[0092] This comparative example is carried out in the manner of Example 1, except that the stacking order of the three layers of crude medicinal material powder is changed, specifically from bottom to top: other crude medicinal material powder, first toxic crude medicinal material powder, and second toxic crude medicinal material powder.
[0093] Comparative Example 3
[0094] This comparative example was carried out in the manner of Example 1, except that the particle sizes of the first toxic medicinal material coarse powder and the second toxic medicinal material coarse powder were controlled to be 30 meshes.
[0095] Comparative Example 4
[0096] This comparative example was carried out in the manner of Example 1, except that: the decoction pieces of the first toxic medicinal material and the second toxic medicinal material were directly used for percolation extraction.
[0097] Comparative Example 5
[0098] This comparative example was carried out in the manner of Example 1, except that during the immersion and percolation process, the liquid level of the ethanol solution was kept flush with the medicinal powder (the ethanol solution just covered the medicinal powder).
[0099] Comparative Example 6
[0100] This comparative example was carried out in the manner of Example 1, except that during the immersion and percolation process, the height from the bottom of the ethanol solution to the liquid level was maintained at 3.3 meters, and the liquid level of the ethanol solution was 30 cm higher than the top of the drug powder.
[0101] Comparative Example 7
[0102] This comparative example was carried out in the manner of Example 1, except that during the immersion and percolation process, the height from the bottom of the ethanol solution to the liquid level was maintained at 3.7 meters, and the liquid level of the ethanol solution was 70 cm higher than the top of the drug powder.
[0103] Comparative Example 8
[0104] This comparative example was carried out in the manner of Example 1, except that no non-woven fabric was placed between each layer of medicine powder.
[0105] Comparative Example 9
[0106] This comparative example was carried out in the manner of Example 1, except that the non-woven fabric placed between each layer of medicine powder had a larger pore size of 100 mesh.
[0107] Comparative Example 10
[0108] This comparative example was carried out in the manner of Example 1, except that the non-woven fabric placed between each layer of medicine powder had a smaller pore size of 500 mesh.
[0109] Comparative Example 11
[0110] This comparative example was carried out in the manner of Example 1, except that the non-woven fabric between each layer of crude medicinal material powder was replaced with a 400-mesh stainless steel screen.
[0111] Application Examples
[0112] Musk wind-chasing pain-relieving ointment fluid extract prepared in the above-mentioned embodiment and comparative example is used to prepare Musk wind-chasing pain-relieving ointment. The preparation method refers to the national standard of Musk wind-chasing pain-relieving ointment (WS-11370 (ZD-1370) -2002-2012Z-2019), and the general process is as follows:
[0113] The formula is: 125g of Musk Chasing Wind and Relief Analgesic Fluid Extract, 50g of Camphor, 25g of Borneol, 37.5g of Methyl Salicylate, 75g of Belladonna Fluid Extract, 50g of Menthol, and 31.25g of Rue Extract. For the above seven flavors, take Musk Chasing Wind and Relief Analgesic Fluid Extract and Belladonna Fluid Extract and mix them for use; the remaining five flavors such as camphor, mix them, add the above fluid extract, mix them, add 4.0 times the amount of a matrix composed of rubber, rosin, zinc oxide, vaseline, lanolin, and liquid paraffin, mix them to make a coating, apply the ointment, cut into sections, cover the lining, and cut into pieces. The specifications of Musk Chasing Wind and Relief Analgesic Ointment are: the patch size is 7cm×10cm, and the ointment content is not less than 1.6g / patch. In order to ensure the parallelism of subsequent tests, all preparations were carried out according to the ointment content of 1.65g / patch for subsequent testing.
[0114] Three samples in each embodiment and comparative example were taken and tested according to the standard of Musk Wind-Chasing Pain-Relieving Ointment. The experimental results are shown in Table 1. To ensure the parallelism of the experiment, the same batch of medicinal materials were used in the experiment, and the detection method was the Musk Wind-Chasing Pain-Relieving Ointment Quality Standard (Standard No.: WS-11370 (ZD-1370) -2002-2012Z-2019).
[0115] Table 1: Test results of finished Musk Wind-Chasing Pain-Relieving Ointment prepared by using Musk Wind-Chasing Fluid Extracts prepared in Examples and Comparative Examples
[0116]
[0117]
[0118] The present inventors analyze the above experimental results as follows:
[0119] Musk wind-chasing analgesic fluid extract obtained by the operation mode of Examples 1-3 is used to prepare Musk Wind-Chasing Analgesic Ointment, and its aconitine limit, strychnine and strychnine content meet the standard requirements. The inventor further tried to use the process flow of Example 1 to prepare Musk Wind-Chasing Analgesic Fluid Extract, and then prepared multiple batches of Musk Wind-Chasing Analgesic Ointment. In terms of the aconitine limit index, the qualified rate is 100%; in terms of the strychnine content range, the qualified rate is 100%; in terms of the strychnine content, the qualified rate is 100%. It shows that the process method of this scheme greatly improves the qualified rate and process stability of Musk Wind-Chasing Analgesic Ointment.
[0120] Comparative Example 1 adopts the traditional production method of Musk Wind-Chasing Pain-Relieving Ointment (specifically referring to the production process of Musk Wind-Chasing Pain-Relieving Fluid Extract), that is, without distinguishing between the crude powder of medicinal materials, the crude powder of the first toxic medicinal materials, and the crude powder of the second toxic medicinal materials, all the medicinal materials are directly powdered and mixed and filled into the percolation tank for percolation. This method is likely to cause the aconitine limit and strychnine content to fail to meet the standard requirements. With regard to the statistical data of multiple batches of products, the unqualified rates of the aconitine limit index and the strychnine content range index are relatively high, resulting in a waste of raw materials and an increase in process costs.
[0121] In comparative example 2, the stacking order of the crude powder of medicinal materials is other crude powder of medicinal materials, first toxic crude powder of medicinal materials, and second toxic crude powder of medicinal materials. The above-mentioned operation method did not fully extract strychnine and brucine in Strychnos nux vomica, resulting in the content of strychnine in the experimental sample being lower than the lower limit. In addition, the inventors also tried to change the arrangement order of the crude powder to the second toxic medicinal powder, other medicinal powder, and first toxic medicinal powder from bottom to top (other specific operation methods are the same as those described in Example 1). This will lead to excessive extraction of aconitine (the TLC detection of aconitine is larger than the reference spot), and insufficient extraction of strychnine (the strychnine content of the prepared Musk Wind-Chasing Pain-Relieving Ointment is lower than the lower limit requirement, far lower than 21 μg in Example 1). Therefore, the stacking order of other medicinal material coarse powders, the first toxic medicinal material coarse powder and the second toxic medicinal material coarse powder in this scheme (from bottom to top, the first toxic medicinal material coarse powder, other medicinal material coarse powders, the second toxic medicinal material coarse powder) is very critical to ensuring that the technical indicators of aconitine and strychnine meet the requirements.
[0122] In Comparative Example 3, the first toxic medicinal material coarse powder and the second toxic medicinal material coarse powder had a small particle size, resulting in excessive extraction of aconitine, which obviously exceeded the limit level. In Comparative Example 4, the first toxic medicinal material and the second toxic medicinal material were not crushed, resulting in low extraction of strychnine and brucine.
[0123] The liquid level of the extracts extracted by percolation in Comparative Examples 5 and 6 was too low, resulting in low extraction amounts of strychnine and strychnine, and even causing the amount of strychnine in the product to be lower than the lower limit requirement. The liquid level of the extracts extracted by percolation in Comparative Example 7 was too high, resulting in excessive extraction of aconitine, exceeding the product limit.
[0124] Comparative Example 8 does not lay non-woven fabrics between each layer of coarse powder, which has little effect on the extraction amount of strychnine and strychnine, but will cause aconitine to exceed the limit. The pore size of the non-woven fabric between each layer of coarse powder in Comparative Example 9 is too large, resulting in an excessive extraction amount of aconitine, and the product does not meet the standard requirements. The pore size of the non-woven fabric between each layer of coarse powder in Comparative Example 10 is relatively small, which affects the process fluency to a certain extent. Although the amount of aconitine does not exceed the limit, the extraction amount of strychnine is too low to meet the standard requirements. Comparative Example 11 lays a 400-mesh stainless steel mesh between each layer. For the limit of aconitine, its effect is close to that of a 400-mesh non-woven fabric, but the stainless steel mesh needs to be folded before entering the extraction tank, and the stainless steel mesh will bend, which brings difficulty to laying, and the cost is high, and it is not easy to cut, etc., so economical non-woven fabrics are selected. Based on the above experimental results, the present inventors found that the mesh size of the laid non-woven fabric can affect the percolation flow rate and thus make a difference in the content of active ingredients in the Musk Chasing Wind Extract when the type of medicinal materials, the crushing mesh size and the filling method are certain. At the same time, the setting of the non-woven fabric makes the distribution of the ethanol solution in the percolation process more uniform, which is beneficial to improving the percolation effect.
[0125] It can be seen from the above experimental data that in order to ensure that the indicators of aconitine, strychnine and strychnine in Musk Wind-Chasing Pain-Relieving Paste meet the requirements, and then to ensure that the product has a qualified rate close to 100%, the following conditions need to be adopted during the percolation extraction process: the coarse powder of the first toxic medicinal material (strychnine) is placed at the bottom of the extraction tank, the coarse powder of other medicinal materials is placed in the middle, and the coarse powder of the second toxic medicinal material (Aconiti Kusnezoffii and Aconitum kusnezoffii) is placed on the upper layer; and a non-woven fabric with a certain pore size (200-400 mesh) is laid between each layer; during the percolation extraction process, the liquid level of the percolation liquid is maintained at a certain height (3.4-3.6 meters, and the columnar accumulation height of the medicinal material powder is 2.9-3.1 meters).
[0126] In the most original process step (Comparative Example 1), the coarse powder of Strychnos nux vomica, raw Radix Aconiti Kusnezoffii and raw Radix Aconiti Kusnezoffii were not layered, but all the medicinal materials were mixed together for percolation extraction, and the liquid level of the percolation extraction was flush with the coarse powder of the medicinal materials. Then the following problems were generated: too much aconitine was extracted, insufficient strychnine was extracted, and although the amount of strychnine extracted met the requirements, it was not high. The inventor placed the coarse powder of medicinal materials containing aconitine (Aconiti Kusnezoffii, Radix Aconiti Kusnezoffii) on the upper layer of the coarse powder pile of medicinal materials, and placed the coarse powder of Strychnos nux vomica on the bottom layer of the coarse powder pile of medicinal materials. The upper pressure is small, and the extraction degree of aconitine is smaller than that of the traditional method; while the upper pressure is large, the extraction degree of strychnine is greater than that of the traditional method. Although the above method can increase the amount of strychnine in the finished product to a certain extent, and aconitine meets the index requirements, the content of strychnine in the finished product is still not very ideal. Although the content of strychnine per tablet is required to be 16 to 48 μg, the content of strychnine is preferably about 20 μg, and the content of strychnine in the finished product obtained in the above manner is still far below the above appropriate level. The inventor further adopted a method of increasing the liquid level of the percolation liquid to increase the pressure to improve the extraction degree of Strychnine. For example, in Comparative Example 8, the method of layering the coarse powder of medicinal materials and increasing the liquid level was adopted. However, the experimental results show that, compared with the traditional process, although this operation can effectively increase the amount of strychnine and brucine, it will also make the amount of aconitine exceed the standard requirements. Therefore, it is relatively difficult to ensure that aconitine and strychnine meet the standard requirements at the same time.
[0127] After many attempts, the inventors found that setting a sieve with a certain aperture (such as non-woven fabric) between each layer of crude medicinal material powder can effectively solve the problem of excessive aconitine after increasing the liquid level, but it does not significantly affect the extraction amount of strychnine and brucine (strychnine can reach about 20μg / patch). If the aperture of the non-woven fabric is too large, the barrier effect on the extraction of aconitine is not ideal, and if the aperture of the non-woven fabric is too small, it will seriously affect the smoothness of the process, resulting in a significant reduction in the extraction amount of strychnine and brucine.
[0128] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A method for preparing a musk wind-chasing and analgesic fluid extract, characterized in that: The method includes the following steps in sequence: S1: crushing the seeds of Strychnos nux vomica to obtain a first toxic medicinal material coarse powder; mixing and crushing the Radix Aconiti Kusnezoffii and Radix Aconiti Kusnezoffii to obtain a second toxic medicinal material coarse powder; mixing and crushing frankincense, myrrh, cloves, cinnamon bark, schizonepeta, siler, geranium, radix scutellariae, centella asiatica, rhizoma drynariae, angelica dahurica, galangal, and dried ginger to obtain other medicinal material coarse powders; S2: placing the first toxic medicinal material coarse powder, other medicinal material coarse powders and the second toxic medicinal material coarse powder into a percolation tank in order from bottom to top; laying non-woven fabric between adjacent coarse powder layers, and then percolating with an ethanol solution to collect the percolation liquid; S3: After the percolate is concentrated, artificial musk is added to obtain the musk wind-chasing and analgesic fluid extract.
2. The method for preparing a musk wind-removing and analgesic fluid extract according to claim 1, characterized in that: In S1, the first toxic medicinal material coarse powder, the second toxic medicinal material coarse powder and other medicinal material coarse powders are all obtained by crushing the medicinal materials and then passing through a 16-20 mesh sieve.
3. The method for preparing a musk wind-removing and analgesic fluid extract according to claim 1, characterized in that: In S2, the pore size of the non-woven fabric is 200-400 mesh; Preferably, the percolation process in S2 is specifically as follows: adding 80% to 95% ethanol solution to the percolation tank, the ratio of ethanol solution to the total mass of medicinal materials being 1.5 to 2.5 L: 1 kg, and then sealing and placing for 3 to 5 hours; then adding 80% to 95% ethanol solution, keeping the stacking height of the medicinal material coarse powder at 2.9 to 3.1 m, and keeping the liquid level of the ethanol solution 40 to 60 cm higher than the upper surface of the medicinal material coarse powder; finally, performing the percolation operation after immersion for 45 to 55 hours, and the percolation speed being 1 to 3 ml / min. kg -1 ; Collect the percolation liquid, the ratio of the percolation liquid to the medicinal materials is 8-12L:1kg.
4. The method for preparing a musk wind-removing and analgesic fluid extract according to claim 1, characterized in that: In S3, the percolation liquid is first concentrated into a semi-finished extract, the relative density of the semi-finished extract is 1.24-1.26 at 40-55°C; then anhydrous ethanol is added to the semi-finished extract, stirred evenly and allowed to stand, and the supernatant is taken, and the usage ratio of anhydrous ethanol to the semi-finished extract is 8-12L:1kg.
5. The method for preparing a musk wind-removing and analgesic fluid extract according to claim 4, characterized in that: In S3, the supernatant is filtered through a 80-120 mesh sieve and concentrated to a relative density of 1.05-1.07 at 40-55° C., and then artificial musk is added and mixed to obtain the musk wind-chasing and analgesic fluid extract.
6. A method for preparing a musk wind-chasing and analgesic fluid extract according to any one of claims 1 to 5, characterized in that: Calculated by weight, the raw materials of the musk wind-chasing and analgesic fluid extract are: 40-50 parts of raw Chuanwu, 40-50 parts of raw Caowu, 40-50 parts of frankincense, 40-50 parts of myrrh, 40-50 parts of raw Strychnos nux vomica, 40-50 parts of cloves, 80-90 parts of cinnamon, 80-90 parts of Nepeta, 80-90 parts of Saposhnikovia divaricata, 80-90 parts of Geranium, 80-90 parts of Perennial Cyperus, 80-90 parts of Centella asiatica, 80-90 parts of Drynaria, 130-140 parts of Angelica dahurica, 130-140 parts of Kaempferia galanga, 130-140 parts of dried ginger, and 0.2-0.3 parts of artificial musk.
7. Musk wind-chasing and analgesic fluid extract prepared by the preparation method according to any one of claims 1 to 5.
8. An external preparation prepared with the Musk Wind-Chuifengzhitong fluid extract as claimed in claim 7 as a raw material.
9. The external preparation according to claim 8, characterized in that: The invention relates to a musk wind-chasing and analgesic ointment; the raw materials of the musk wind-chasing and analgesic ointment include, by weight, 50-60 parts of musk wind-chasing and analgesic fluid extract, 20-25 parts of camphor, 10-15 parts of borneol, 14-20 parts of methyl salicylate, 20-25 parts of menthol, 12-18 parts of rue extract and 30-40 parts of belladonna extract.
10. The method for preparing the Musk Wind-Chasing Pain-Relieving Ointment according to claim 9, characterized in that: The first mixed extract is obtained by mixing the musk wind-chasing and analgesic fluid extract with the belladonna fluid extract; the second mixed extract is obtained by mixing camphor, borneol, methyl salicylate, menthol and rue extract; after the first mixed extract and the second mixed extract are mixed, a matrix consisting of rubber, rosin, zinc oxide, vaseline, lanolin and liquid paraffin is added, the mixture is mixed to form a coating, the coating is applied, the coating is cut into sections, the coating is covered and the coating is cut into blocks.
Citation Information
Patent Citations
Preparation method of Dan'e Fukang preparation
CN115518136A
Muskiness acesodyne ointment of chasing wind, and preparation method
CN1872235A
